<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01166646</url>
  </required_header>
  <id_info>
    <org_study_id>000-0551-202</org_study_id>
    <nct_id>NCT01166646</nct_id>
  </id_info>
  <brief_title>Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the investigational lotion is an effective
      treatment of moderate to severe plaque psoriasis in comparison to an approved cream.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adrenal Suppression Potential</measure>
    <time_frame>After 1-2 weeks dose</time_frame>
    <description>Hypothalamic Pituitary-Adrenal (HPA)-Axis responses to Cosyntropin Stimulation Testing (CST) were dichotomized to normal and abnormal. An abnormal HPA Axis response (HPA Suppression) was defined as a 30-minute post-stimulation serum cortisol level of ≤18 μg/dL at the end of treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Properties (Cmax)</measure>
    <time_frame>Day 8</time_frame>
    <description>Comparison of PK results (peak concentration in plasma [Cmax]) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Properties (Tmax)</measure>
    <time_frame>Day 8</time_frame>
    <description>Comparison of PK results (time to peak concentration [Tmax]) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Properties (AUC)</measure>
    <time_frame>Day 8</time_frame>
    <description>Comparison of PK results (area under the curve [AUC] from time 0 to infinity) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Disease Severity (Success)</measure>
    <time_frame>Day 15</time_frame>
    <description>Overall disease severity (ODS) will be recorded at baseline, Day 8, and Day 15 on a 0 (clear) to 4 (severe/very severe) point scale. ODS evaluations will be dichotomized to &quot;success&quot; and &quot;failure&quot; with success defined as a grade of 1 or 0 at the end of treatment (EOT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Whose Signs of Psoriasis Was Designated &quot;Success&quot;</measure>
    <time_frame>Day 15</time_frame>
    <description>Signs of psoriasis including scaling, erythema, and plaque elevation will be recorded at baseline, Day 8, and Day 15 on a 0 (clear) to 4 (severe/very severe) point scale. Each of the signs of psoriasis will be dichotomized to a) &quot;success&quot; and &quot;failure&quot; with success defined as a grade of 1 or 0 at the End of Treatment (EOT; i.e., the visit at which psoriasis has cleared [Day 8 or Day 15] or end of the assigned treatment period).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Halobetasol Proprionate Lotion 0.05%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects randomized to receive lotion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Halobetasol Proprionate Cream 0.05%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects randomized to receive cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Halobetasol Proprionate Lotion 0.05%</intervention_name>
    <description>Apply 3.5 grams twice daily for 1-2 weeks</description>
    <arm_group_label>Halobetasol Proprionate Lotion 0.05%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Halobetasol Proprionate Cream 0.05%</intervention_name>
    <description>Apply 3.5 grams twice daily for 1-2 weeks</description>
    <arm_group_label>Halobetasol Proprionate Cream 0.05%</arm_group_label>
    <other_name>Ultravate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects are male or non-pregnant female; 18 years of age at the time of screening.

          -  Subjects provide Institutional Review Board (IRB) approved written informed consent
             for participating in this study.

          -  Subjects have a clinical diagnosis of stable plaque psoriasis involving a minimum of
             20% body surface area and an Overall Disease Severity (ODS) score on the designated
             treatment area of at least 3 as determined by the evaluating investigator.

          -  Subjects are willing and able to apply the study medication as directed, comply with
             study instructions and commit to all follow-up visits for the duration of the study.

          -  Women of childbearing potential (WOCBP) must have a negative urine pregnancy test at
             the Screening (Part B) and Baseline Visits and agree to use an effective form of birth
             control for the duration of the study (abstinence, stabilized on oral contraceptives
             or contraceptive patches for at least three months, implant, injection, IUD,
             NuvaRing®, condom and spermicidal or diaphragm and spermicidal). Abstinence is an
             acceptable form of birth control for subjects who are not sexually active. Subjects
             who become sexually active during the trial must agree to use an effective,
             non-prohibited form of birth control for the duration of the study.

        Exclusion Criteria:

          -  Subjects have spontaneously improving or rapidly deteriorating plaque psoriasis, or
             have guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.

          -  Subjects have a physical condition which, in the Investigator's opinion, might impair
             evaluation of plaque psoriasis, adrenal axis function (e.g., Addison's Disease,
             Cushing's Syndrome) or which exposes the subject to an unacceptable risk by study
             participation.

          -  Subjects have used any phototherapy (including laser), photo-chemotherapy or systemic
             psoriasis therapy including methotrexate, retinoids, cyclosporine or biologics within
             30 days prior to the initiation of study medication treatment.

          -  Subjects have used systemic corticosteroids (including oral or intramuscular) or
             topical, inhaled or intranasal corticosteroids within 30 or 14 days, respectively,
             prior to Part B of the Screening Visit and/or subjects have used systemic or topical
             corticosteroids between the Screening Visit and the initiation of treatment.

          -  Subjects have had prolonged exposure to natural or artificial sources of ultraviolet
             radiation within 30 days prior to the initiation of treatment or are intending to have
             such exposure during the study that is thought by the Investigator to likely modify
             the subject's disease.

          -  Subjects have used topical psoriatic therapy including tar, anthralin, retinoids,
             vitamin D analogs (e.g., Dovonex®) within 14 days prior to the initiation of study
             medication treatment.

          -  Subjects have used emollients/moisturizers on areas to be treated within one day prior
             to the initiation of study medication treatment.

          -  Subjects are currently using lithium or plaquenil.

          -  Subjects are currently using a beta-blocking medication (e.g., propanolol) or
             angiotensin converting enzyme (ACE) inhibitors at a dose that has not been stabilized,
             in the opinion of the Investigator.

          -  Subjects have a history of sensitivity to any of the ingredients in the study
             medication.

          -  Subjects are pregnant, nursing or planning a pregnancy during the study period.

          -  Subjects are currently enrolled in an investigational drug or device study.

          -  Subjects have received an investigational drug or an investigational device within 30
             days prior to screening.

          -  Subjects have been previously enrolled in this study and treated with the study
             medication.

          -  Subjects have irregular sleep schedules or work night shifts (cortisol levels exhibit
             physiological diurnal variation).

          -  Subjects have a screening CST with a post 30-minute stimulation cortisol level of ≤ 18
             µg/dL.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Therapeutics Clinical Research</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Skin Care Research (dba Skin Care Research)</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Skin Centre</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology, Laser &amp; Vein Specialists of the Carolinas PLLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2010</study_first_submitted>
  <study_first_submitted_qc>July 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2010</study_first_posted>
  <results_first_submitted>March 10, 2016</results_first_submitted>
  <results_first_submitted_qc>April 11, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2016</results_first_posted>
  <disposition_first_submitted>December 5, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 5, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 7, 2012</disposition_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Halobetasol</mesh_term>
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: August 2010 to May 2011
The location of clinical sites included private dermatology clinics and clinical research centers.</recruitment_details>
      <pre_assignment_details>All subjects who met the entry criteria were randomized and enrolled into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Halobetasol Proprionate Lotion 0.05%</title>
          <description>Subjects randomized to receive lotion
Halobetasol Proprionate Lotion 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
        </group>
        <group group_id="P2">
          <title>Halobetasol Proprionate Cream 0.05%</title>
          <description>Subjects randomized to receive cream
Halobetasol Proprionate Cream 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Intent-To-Treat (ITT) population included all participants enrolled in the study who were dispensed and applied test article at least once and had at least one follow-up visit after the Baseline visit (Visit 2). All 43 enrolled subjects were included in the ITT population.</population>
      <group_list>
        <group group_id="B1">
          <title>Halobetasol Proprionate Lotion 0.05%</title>
          <description>Subjects randomized to receive lotion
Halobetasol Proprionate Lotion 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
        </group>
        <group group_id="B2">
          <title>Halobetasol Proprionate Cream 0.05%</title>
          <description>Subjects randomized to receive cream
Halobetasol Proprionate Cream 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="43"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.5" spread="9.28"/>
                    <measurement group_id="B2" value="47.7" spread="12.57"/>
                    <measurement group_id="B3" value="48.5" spread="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adrenal Suppression Potential</title>
        <description>Hypothalamic Pituitary-Adrenal (HPA)-Axis responses to Cosyntropin Stimulation Testing (CST) were dichotomized to normal and abnormal. An abnormal HPA Axis response (HPA Suppression) was defined as a 30-minute post-stimulation serum cortisol level of ≤18 μg/dL at the end of treatment.</description>
        <time_frame>After 1-2 weeks dose</time_frame>
        <population>Analysis shown is based on the ITT population, defined as all enrolled participants who were randomized and applied at least one dose of the test article.</population>
        <group_list>
          <group group_id="O1">
            <title>Halobetasol Proprionate Lotion 0.05%</title>
            <description>Subjects randomized to receive lotion
Halobetasol Proprionate Lotion 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Halobetasol Proprionate Cream 0.05%</title>
            <description>Subjects randomized to receive cream
Halobetasol Proprionate Cream 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adrenal Suppression Potential</title>
          <description>Hypothalamic Pituitary-Adrenal (HPA)-Axis responses to Cosyntropin Stimulation Testing (CST) were dichotomized to normal and abnormal. An abnormal HPA Axis response (HPA Suppression) was defined as a 30-minute post-stimulation serum cortisol level of ≤18 μg/dL at the end of treatment.</description>
          <population>Analysis shown is based on the ITT population, defined as all enrolled participants who were randomized and applied at least one dose of the test article.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Normal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abnormal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Properties (Cmax)</title>
        <description>Comparison of PK results (peak concentration in plasma [Cmax]) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacokinetic properties were evaluated in a subgroup of 12 adult subjects per arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Halobetasol Proprionate Lotion 0.05%</title>
            <description>Subjects randomized to receive lotion
Halobetasol Proprionate Lotion 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Halobetasol Proprionate Cream 0.05%</title>
            <description>Subjects randomized to receive cream
Halobetasol Proprionate Cream 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Properties (Cmax)</title>
          <description>Comparison of PK results (peak concentration in plasma [Cmax]) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.</description>
          <population>Pharmacokinetic properties were evaluated in a subgroup of 12 adult subjects per arm.</population>
          <units>pg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.9" spread="106.9"/>
                    <measurement group_id="O2" value="136.2" spread="71.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Properties (Tmax)</title>
        <description>Comparison of PK results (time to peak concentration [Tmax]) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacokinetic properties were evaluated in a subgroup of 12 adult subjects per arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Halobetasol Proprionate Lotion 0.05%</title>
            <description>Subjects randomized to receive lotion
Halobetasol Proprionate Lotion 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Halobetasol Proprionate Cream 0.05%</title>
            <description>Subjects randomized to receive cream
Halobetasol Proprionate Cream 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Properties (Tmax)</title>
          <description>Comparison of PK results (time to peak concentration [Tmax]) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.</description>
          <population>Pharmacokinetic properties were evaluated in a subgroup of 12 adult subjects per arm.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="3" lower_limit="0" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetic Properties (AUC)</title>
        <description>Comparison of PK results (area under the curve [AUC] from time 0 to infinity) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacokinetics properties were evaluated in a subgroup of 12 adult subjects per arm.</population>
        <group_list>
          <group group_id="O1">
            <title>Halobetasol Proprionate Lotion 0.05%</title>
            <description>Subjects randomized to receive lotion
Halobetasol Proprionate Lotion 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Halobetasol Proprionate Cream 0.05%</title>
            <description>Subjects randomized to receive cream
Halobetasol Proprionate Cream 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Properties (AUC)</title>
          <description>Comparison of PK results (area under the curve [AUC] from time 0 to infinity) between the two Treatment Groups will be conducted following the last application of the medication on Day 8.</description>
          <population>Pharmacokinetics properties were evaluated in a subgroup of 12 adult subjects per arm.</population>
          <units>pg*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1267.7" spread="89.84"/>
                    <measurement group_id="O2" value="1229.8" spread="67.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Disease Severity (Success)</title>
        <description>Overall disease severity (ODS) will be recorded at baseline, Day 8, and Day 15 on a 0 (clear) to 4 (severe/very severe) point scale. ODS evaluations will be dichotomized to “success” and “failure” with success defined as a grade of 1 or 0 at the end of treatment (EOT).</description>
        <time_frame>Day 15</time_frame>
        <population>Analysis shown is based on the ITT population at Day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>Halobetasol Proprionate Lotion 0.05%</title>
            <description>Subjects randomized to receive lotion
Halobetasol Proprionate Lotion 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Halobetasol Proprionate Cream 0.05%</title>
            <description>Subjects randomized to receive cream
Halobetasol Proprionate Cream 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Disease Severity (Success)</title>
          <description>Overall disease severity (ODS) will be recorded at baseline, Day 8, and Day 15 on a 0 (clear) to 4 (severe/very severe) point scale. ODS evaluations will be dichotomized to “success” and “failure” with success defined as a grade of 1 or 0 at the end of treatment (EOT).</description>
          <population>Analysis shown is based on the ITT population at Day 15.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Whose Signs of Psoriasis Was Designated &quot;Success&quot;</title>
        <description>Signs of psoriasis including scaling, erythema, and plaque elevation will be recorded at baseline, Day 8, and Day 15 on a 0 (clear) to 4 (severe/very severe) point scale. Each of the signs of psoriasis will be dichotomized to a) “success” and “failure” with success defined as a grade of 1 or 0 at the End of Treatment (EOT; i.e., the visit at which psoriasis has cleared [Day 8 or Day 15] or end of the assigned treatment period).</description>
        <time_frame>Day 15</time_frame>
        <population>Analysis shown is based on the number of subjects whose Signs of Psoriasis was designated &quot;Success&quot; (ITT population) at Day 15.</population>
        <group_list>
          <group group_id="O1">
            <title>Halobetasol Proprionate Lotion 0.05%</title>
            <description>Subjects randomized to receive lotion
Halobetasol Proprionate Lotion 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
          <group group_id="O2">
            <title>Halobetasol Proprionate Cream 0.05%</title>
            <description>Subjects randomized to receive cream
Halobetasol Proprionate Cream 0.05%: Apply 3.5 grams twice daily for up to 2 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Whose Signs of Psoriasis Was Designated &quot;Success&quot;</title>
          <description>Signs of psoriasis including scaling, erythema, and plaque elevation will be recorded at baseline, Day 8, and Day 15 on a 0 (clear) to 4 (severe/very severe) point scale. Each of the signs of psoriasis will be dichotomized to a) “success” and “failure” with success defined as a grade of 1 or 0 at the End of Treatment (EOT; i.e., the visit at which psoriasis has cleared [Day 8 or Day 15] or end of the assigned treatment period).</description>
          <population>Analysis shown is based on the number of subjects whose Signs of Psoriasis was designated &quot;Success&quot; (ITT population) at Day 15.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scaling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plaque elevation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>AEs were collected from study screening (performed 14 days prior to baseline/first dose) to end of study treatment or participant termination. AEs that continued beyond completion/termination were followed until resolution or stabilization.</time_frame>
      <desc>The Safety population included all subjects enrolled in the study who were dispensed the test article at least once.</desc>
      <group_list>
        <group group_id="E1">
          <title>Halobetasol Proprionate Lotion 0.05%</title>
          <description>Subjects randomized to receive lotion
Halobetasol Proprionate Lotion 0.05%: Apply 3.5 grams twice daily for 1-2 weeks</description>
        </group>
        <group group_id="E2">
          <title>Halobetasol Proprionate Cream 0.05%</title>
          <description>Subjects randomized to receive cream
Halobetasol Proprionate Cream 0.05%: Apply 3.5 grams twice daily for 1-2 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pallor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Throat infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Procedural nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ACTH stimulation test abnormal</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 30 days prior to public dissemination. The PI may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research, Therapeutics Inc.</name_or_title>
      <organization>Therapeutics, Inc.</organization>
      <phone>858-571-1800</phone>
      <email>clinicalresearch@therapeuticsinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

